arthritis advocacy news and regulatory letters

Advocacy News & Regulatory Letters

February 19, 2019

Arthritis Foundation Comments on Annual Notice of Benefit and Payment Parameters

On February 19, the Arthritis Foundation submitted comments to the Department of Health and Human Services (HHS) on the proposed Notice of Benefit and Payment Parameters for 2019. The proposed regulation affects the individual health insurance market and the health care exchanges. Our comments focused on proposed increases in premiums and out-of-pocket costs as well as impacts on access to needed medications for people with arthritis. Read the letter here.

February 7, 2019

Arthritis Foundation Submits Comments on Medicaid Waiver from Tennessee

The Arthritis Foundation submitted comments to the federal Department of Health and Human Services on the state of Tennessee’s 1115 Medicaid waiver. The waiver seeks to add a work and community engagement component to the state’s Medicaid program. The proposal would require enrollees to report at least 80 hours of work per month, or that they meet certain exemptions under the proposal. A major consequence is that administrative burdens would increase for enrollees, and implementing this proposal would be expensive for the state. Read the letter here.

February 1, 2019

Arthritis Foundation Joins Over 70 Organizations Urging Reauthorization of the Pediatric Subspecialty Loan Repayment Program

On February 1, several dozen organizations dedicated to improving the health and wellbeing of children and adolescents wrote leaders in Congress to reauthorize a federal loan repayment program that supports pediatric subspecialists. The program provides loan repayment for physicians who specialize in pediatrics – such as pediatric rheumatology – if they commit to working in an underserved area of the country for a period of time. Read the letter here.

January 29, 2019

Arthritis Foundation and American College of Rheumatology to Hold Briefing on Arthritis in the Military

On February 13, the Arthritis Foundation and American College of Rheumatology will hold a briefing on Capitol Hill to highlight the epidemic of arthritis among U.S. military service members and veterans. Read more here.

January 24, 2019

Arthritis Foundation Comments on Medicare Advantage and Part D Proposed Rule

On January 24, the Arthritis Foundation submitted comments to the Centers for Medicare and Medicaid Services on a proposed regulation affecting Medicare Advantage and Medicare Part D, the prescription drug program. The Foundation’s comments highlighted concerns with last fall’s guidance that permits step therapy in Medicare Advantage plans. We also applauded the administration’s action to address pharmacy gag clauses, which prevent pharmacists from telling patients when it might be cheaper to pay for medication with cash rather than through insurance. Read the comments here.

January 18, 2019

Arthritis Foundation Comments on Medicaid Waiver from Oklahoma

The Arthritis Foundation submitted comments to the federal Department of Health and Human Services on the state of Oklahoma’s 1115 Medicaid waiver. The waiver seeks to add a work requirement to the state’s Medicaid program. A major consequence of the proposal is that it will increase the administrative burden on all patients, including those with chronic diseases like arthritis who depend on Medicaid for health care. Read the letter here.

January 4, 2019

Arthritis Foundation Comments on Medicaid Waiver from Virginia

The Arthritis Foundation submitted comments to the federal Department of Health and Human Services on the state of Virginia’s 1115 Medicaid wavier. The waiver seeks to add a work and community engagement component to the state’s Medicaid program. Arthritis is the leading cause of work-related disability in the United States and these types of proposals can create barriers to accessing or maintaining health care coverage. Read the letter here.

January 2, 2019

Arthritis Foundation Comments on Medicare IPI Model

The Arthritis Foundation submitted comments to the federal Department of Health and Human Services on a proposal that would change how physician-administered drugs are paid for under the Medicare program. As described in the proposal, we believe the international pricing index (IPI) model’s projected benefits are outweighed by potential negative impacts on patient access. Read the letter here.

 

Get caught up on news from past years: